Equities

Nang Kuang Pharmaceutical Co Ltd

1752:TAI

Nang Kuang Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (TWD)44.50
  • Today's Change0.25 / 0.56%
  • Shares traded90.83k
  • 1 Year change-19.09%
  • Beta--
Data delayed at least 20 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of TWD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments378403418
Total Receivables, Net376387351
Total Inventory705780640
Prepaid expenses787182
Other current assets, total------
Total current assets1,5381,6401,491
Property, plant & equipment, net1,9501,6241,699
Goodwill, net------
Intangibles, net5.203.875.21
Long term investments315282194
Note receivable - long term------
Other long term assets8.587.039.39
Total assets3,8563,5853,429
LIABILITIES
Accounts payable167254224
Accrued expenses------
Notes payable/short-term debt580370480
Current portion long-term debt/capital leases131414
Other current liabilities, total523403355
Total current liabilities1,2831,0401,073
Total long term debt132639
Total debt606409533
Deferred income tax01.200.26
Minority interest------
Other liabilities, total18410676
Total liabilities1,4791,1741,189
SHAREHOLDERS EQUITY
Common stock1,0101,0101,010
Additional paid-in capital427457482
Retained earnings (accumulated deficit)940944748
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(0.03)0.02(0.04)
Total equity2,3772,4112,240
Total liabilities & shareholders' equity3,8563,5853,429
Total common shares outstanding101101101
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.